decitabine

[Proceedings of the National Academy of Sciences of the United States of America] DNA-methylation inhibitors have previously been shown to promote regulatory T cell responses and, in the present study, investigators evaluated their potential to ameliorate chronic and acute animal models of rheumatoid arthritis.

[Cancer Medicine] To evaluate the tolerance and efficacy of prophylactic donor lymphocyte infusion in patients with unfavourable gene mutations such as FLT3‐ITD, TP53, ASXL1, DNMT3A or TET2, scientists performed a prospective, single‐arm study.

[Bio-Path Holdings, Inc.] Bio-Path Holdings, Inc. announced the successful completion of the safety run-in of the Stage II of the Phase II clinical study of prexigebersen, a liposomal Grb2 antisense, for the treatment of acute myeloid leukemia (AML), in combination with frontline therapies, decitabine and venetoclax, in AML patients.

[Nature Communications] Anti-tumor activities, cytokine production, and proliferation were enhanced in decitabine-treated chimeric antigen receptor T cells both in vitro and in vivo.

[Cancer Research] An unbiased RNA-seq approach was developed to interrogate DAC-induced transcriptome changes in AML cell lines with or without a deletion of chromosomes 7q, 5q or 17p. Hypomethylating agent treatment preferentially upregulated several hemizygous tumor suppressor genes in this genomic region, significantly derepressing endogenous retrovirus (ERV)3-1 with promoter demethylation, enhanced chromatin accessibility, and increased H3K4me3 levels.

[Astex Pharmaceuticals, Inc.] Astex Pharmaceuticals, Inc. announced it has entered into a Cooperative Research and Development Agreement with the US National Cancer Institute, part of National Institutes of Health. The agreement calls for a range of new clinical and translational studies of oral decitabine and cedazuridine tablets as an anticancer agent to be conducted in collaboration with Astex.